Video

Orasis phase 2b data for CSF-1 presented at ASCRS

Author(s):

Sheryl Stevenson
Conferences|ASCRS

For the first time, Orasis Pharmaceutical's phase 2b data for the company's novel candidate for the treatment of presbyopia, CSF-1, a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle, will be presented during ASCRS by Marjan Farid, MD, and Preeya Gupta, MD. The company recently released its phase 3 topline results. Orasis' Paul Smith, president and COO, talks with Ophthalmology Times' Sheryl Stevenson about this data and the findings' relevance to patients and providers.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
(Image credit: AdobeStock/WS Studio 1985)
June 25th 2025

Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Meeting the need for low vision services with wearable tech
June 19th 2025

Q&A: Meeting the need for low vision services with wearable tech

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/peopleimages.com) Rethinking end points in AMD: the power of OCT imaging with Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
June 18th 2025

Rethinking end points in AMD: the power of OCT imaging with Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

Ocular Therapeutix to present at Clinical Trials at the Summit 2025
June 18th 2025

Ocular Therapeutix to present at Clinical Trials at the Summit 2025

© 2025 MJH Life Sciences

All rights reserved.